Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PAHC Phibro Animal Health	$23.88 -0.3%	$21.85	$16.16 ▼ $26.55	$967.94M	0.74	207,387 shs	247,450 shs
RARE Ultragenyx Pharmaceutical	$37.14 -0.6%	$36.43	$29.59 ▼ $60.37	$3.51B	0.25	837,463 shs	1.20 million shs
RYTM Rhythm Pharmaceuticals	$61.99 +0.8%	$62.34	$39.46 ▼ $69.89	$3.94B	2.3	551,150 shs	719,497 shs
SWTX SpringWorks Therapeutics	$46.96 +0.4%	$45.13	$28.21 ▼ $62.00	$3.54B	0.7	2.48 million shs	10.43 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PAHC Phibro Animal Health	0.00%	-0.21%	+3.74%	+9.04%	+36.61%
RARE Ultragenyx Pharmaceutical	0.00%	-0.93%	+4.59%	-5.21%	-0.75%
RYTM Rhythm Pharmaceuticals	0.00%	-1.45%	-0.03%	+19.12%	+49.77%
SWTX SpringWorks Therapeutics	0.00%	+0.38%	+1.49%	-5.87%	+29.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PAHC Phibro Animal Health	3.8491 of 5 stars	0.8	4.0	2.5	1.1	2.8	3.3	2.5
RARE Ultragenyx Pharmaceutical	4.2745 of 5 stars	3.5	3.0	0.0	3.8	2.9	2.5	0.6
RYTM Rhythm Pharmaceuticals	4.0892 of 5 stars	3.5	3.0	0.0	4.3	2.7	0.8	0.6
SWTX SpringWorks Therapeutics	1.6311 of 5 stars	3.1	2.0	0.0	0.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PAHC Phibro Animal Health	1.67	Reduce	$20.80	-12.90% Downside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$87.00	134.25% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	23.59% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.95% Upside

Current Analyst Ratings Breakdown

Latest PAHC, RARE, RYTM, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
5/9/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$64.00 ➝ $65.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PAHC Phibro Animal Health	$1.02B	0.95	$2.11 per share	11.30	$6.34 per share	3.77
RARE Ultragenyx Pharmaceutical	$560.23M	6.27	N/A	N/A	$2.76 per share	13.46
RYTM Rhythm Pharmaceuticals	$130.13M	30.31	N/A	N/A	$0.35 per share	177.11
SWTX SpringWorks Therapeutics	$191.59M	18.47	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PAHC Phibro Animal Health	$2.42M	$0.78	30.62	11.37	0.45	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest PAHC, RARE, RYTM, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest PAHC, RARE, RYTM, and SWTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PAHC Phibro Animal Health	2.67	2.91	1.23
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PAHC Phibro Animal Health	99.34%
RARE Ultragenyx Pharmaceutical	97.67%
RYTM Rhythm Pharmaceuticals	N/A
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
PAHC Phibro Animal Health	50.07%
RARE Ultragenyx Pharmaceutical	5.50%
RYTM Rhythm Pharmaceuticals	6.10%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

PAHC, RARE, RYTM, and SWTX Headlines

Recent News About These Companies

SG Americas Securities LLC Buys 9,409 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 21 at 3:29 AM | marketbeat.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20 at 8:25 AM | quiverquant.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20 at 8:00 AM | globenewswire.com

GAMMA Investing LLC Buys 13,270 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 19 at 3:03 AM | marketbeat.com

Comparing SpringWorks Therapeutics (NASDAQ:SWTX) & Genenta Science (NASDAQ:GNTA)

June 18, 2025 | americanbankingnews.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts

June 17, 2025 | marketbeat.com

Biotech Stocks To Consider - June 16th

June 16, 2025 | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading Volume - Here's Why

June 16, 2025 | marketbeat.com

FNY Investment Advisers LLC Purchases New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16, 2025 | marketbeat.com

Assenagon Asset Management S.A. Takes $3.52 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16, 2025 | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?

June 9, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC

June 5, 2025 | marketbeat.com

RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 31, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 28, 2025 | marketbeat.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 27, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

ProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

PAHC, RARE, RYTM, and SWTX Company Descriptions

Phibro Animal Health NASDAQ:PAHC

$23.88 -0.08 (-0.33%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.89 +0.01 (+0.04%)

As of 06/20/2025 04:08 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Ultragenyx Pharmaceutical NASDAQ:RARE

$37.14 -0.21 (-0.56%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$37.56 +0.41 (+1.12%)

As of 06/20/2025 06:23 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.99 +0.51 (+0.83%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$61.28 -0.72 (-1.15%)

As of 06/20/2025 06:07 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

SpringWorks Therapeutics NASDAQ:SWTX

$46.96 +0.18 (+0.38%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$46.96 -0.01 (-0.01%)

As of 06/20/2025 06:15 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time